BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 10, 2012
View Archived Issues
New ESC guidelines recommend use of ticagrelor
Read More
Symphogen licenses Sym-004 to Merck KGaA
Read More
FDA continues review of crofelemer NDA beyond PDUFA date
Read More
ValiRx reports data on VAL-201 for breast cancer
Read More
Novel HDAC inhibitors prepared at Dana Farber Cancer Institute
Read More
CSIR patents novel agents for cancer
Read More
Glenmark Pharmaceuticals prepares new MPGES-1 inhibitors
Read More
Novel DGAT1 inhibitors synthesized by Merck & Co.
Read More
Scientists at BioRelix present new flavin derivatives
Read More
Phase II zabofloxacin results presented at ICAAC
Read More
Generon begins clinical studies of IL-22 product
Read More
FG-3019 safe and well tolerated in phase II study in IPF
Read More
Aileron Therapeutics reports on new therapeutic drug program
Read More
NeurOp receives NIH funding for ischemia research
Read More
PM-01183 receives positive opinion for orphan drug status in E.U.
Read More
Sanofi develops new 11-beta-HSD1 inhibitors for the treatment of diabetes
Read More
InSite Vision completes enrollment of DOUBle study
Read More
Janssen makes submissions to the FDA for two different Xarelto sNDAs
Read More
SFJ and Pfizer sign agreement to codevelop treatment for advanced NSCLC
Read More
Atu-111 shows efficacy in preclinical model of acute lung injury
Read More
Phase I/II trial of Astex's HSP 90 inhibitor begins
Read More
Cedars-Sinai Heart Institute receives funding to further study cardiac stem cells
Read More
AstraZeneca discontinues development of candidate in obesity collaboration with Palatin
Read More
Actinium to begin screening patients for second cohort of phase I/II trial in AML
Read More